vs
NEUROCRINE BIOSCIENCES INC（NBIX）与Rollins, Inc.（ROL）财务数据对比。点击上方公司名可切换其他公司
Rollins, Inc.的季度营收约是NEUROCRINE BIOSCIENCES INC的1.1倍（$906.4M vs $805.5M），NEUROCRINE BIOSCIENCES INC净利率更高（19.1% vs 11.9%，领先7.2%），NEUROCRINE BIOSCIENCES INC同比增速更快（28.3% vs 10.2%），NEUROCRINE BIOSCIENCES INC自由现金流更多（$386.0M vs $111.2M），过去两年NEUROCRINE BIOSCIENCES INC的营收复合增速更高（25.0% vs 0.8%）
Neurocrine Biosciences是1992年成立的美国生物制药企业，总部位于加利福尼亚州圣地亚哥，截至2024年10月首席执行官为Kyle Gano。公司专注于神经及内分泌相关疾病的疗法研发，旗下药物缬苯那嗪（商品名Ingrezza）于2017年获美国批准，用于治疗成人迟发性运动障碍。
Rollins, Inc.是北美知名虫害防治服务商，面向住宅及商业客户提供专业防控服务。公司依托Orkin、HomeTeam Pest Defense等多家全资子公司布局全球业务，覆盖北美、英国等市场，在民用及商用虫害治理领域具备深厚的行业积累与品牌优势。
NBIX vs ROL — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $805.5M | $906.4M |
| 净利润 | $153.7M | $107.8M |
| 毛利率 | 97.8% | — |
| 营业利润率 | 26.2% | 16.1% |
| 净利率 | 19.1% | 11.9% |
| 营收同比 | 28.3% | 10.2% |
| 净利润同比 | 49.1% | 2.5% |
| 每股收益（稀释后） | $1.49 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | — | $906.4M | ||
| Q4 25 | $805.5M | $912.9M | ||
| Q3 25 | $794.9M | $1.0B | ||
| Q2 25 | $687.5M | $999.5M | ||
| Q1 25 | $572.6M | $822.5M | ||
| Q4 24 | $627.7M | $832.2M | ||
| Q3 24 | $622.1M | $916.3M | ||
| Q2 24 | $590.2M | $891.9M |
| Q1 26 | — | $107.8M | ||
| Q4 25 | $153.7M | $116.4M | ||
| Q3 25 | $209.5M | $163.5M | ||
| Q2 25 | $107.5M | $141.5M | ||
| Q1 25 | $7.9M | $105.2M | ||
| Q4 24 | $103.1M | $105.7M | ||
| Q3 24 | $129.8M | $136.9M | ||
| Q2 24 | $65.0M | $129.4M |
| Q1 26 | — | — | ||
| Q4 25 | 97.8% | — | ||
| Q3 25 | 98.2% | — | ||
| Q2 25 | 98.4% | — | ||
| Q1 25 | 98.4% | — | ||
| Q4 24 | 98.5% | — | ||
| Q3 24 | 98.7% | — | ||
| Q2 24 | 98.4% | — |
| Q1 26 | — | 16.1% | ||
| Q4 25 | 26.2% | 17.5% | ||
| Q3 25 | 30.1% | 21.9% | ||
| Q2 25 | 21.2% | 19.8% | ||
| Q1 25 | 4.1% | 17.3% | ||
| Q4 24 | 22.6% | 18.1% | ||
| Q3 24 | 29.5% | 20.9% | ||
| Q2 24 | 24.6% | 20.4% |
| Q1 26 | — | 11.9% | ||
| Q4 25 | 19.1% | 12.8% | ||
| Q3 25 | 26.4% | 15.9% | ||
| Q2 25 | 15.6% | 14.2% | ||
| Q1 25 | 1.4% | 12.8% | ||
| Q4 24 | 16.4% | 12.7% | ||
| Q3 24 | 20.9% | 14.9% | ||
| Q2 24 | 11.0% | 14.5% |
| Q1 26 | — | $0.22 | ||
| Q4 25 | $1.49 | $0.24 | ||
| Q3 25 | $2.04 | $0.34 | ||
| Q2 25 | $1.06 | $0.29 | ||
| Q1 25 | $0.08 | $0.22 | ||
| Q4 24 | $1.00 | $0.22 | ||
| Q3 24 | $1.24 | $0.28 | ||
| Q2 24 | $0.63 | $0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $713.0M | $116.5M |
| 总债务越低越好 | — | $650.6M |
| 股东权益账面价值 | $3.3B | $1.4B |
| 总资产 | $4.6B | $3.2B |
| 负债/权益比越低杠杆越低 | — | 0.47× |
8季度趋势，按日历期对齐
| Q1 26 | — | $116.5M | ||
| Q4 25 | $713.0M | $100.0M | ||
| Q3 25 | $340.2M | $127.4M | ||
| Q2 25 | $264.0M | $123.0M | ||
| Q1 25 | $194.1M | $201.2M | ||
| Q4 24 | $233.0M | $89.6M | ||
| Q3 24 | $349.1M | $95.3M | ||
| Q2 24 | $139.7M | $106.7M |
| Q1 26 | — | $650.6M | ||
| Q4 25 | — | $486.1M | ||
| Q3 25 | — | $485.7M | ||
| Q2 25 | — | $485.3M | ||
| Q1 25 | — | $485.5M | ||
| Q4 24 | — | $395.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $3.3B | $1.4B | ||
| Q3 25 | $3.0B | $1.5B | ||
| Q2 25 | $2.7B | $1.4B | ||
| Q1 25 | $2.5B | $1.4B | ||
| Q4 24 | $2.6B | $1.3B | ||
| Q3 24 | $2.7B | $1.3B | ||
| Q2 24 | $2.5B | $1.2B |
| Q1 26 | — | $3.2B | ||
| Q4 25 | $4.6B | $3.1B | ||
| Q3 25 | $4.3B | $3.2B | ||
| Q2 25 | $3.9B | $3.2B | ||
| Q1 25 | $3.7B | $2.9B | ||
| Q4 24 | $3.7B | $2.8B | ||
| Q3 24 | $3.5B | $2.8B | ||
| Q2 24 | $3.3B | $2.8B |
| Q1 26 | — | 0.47× | ||
| Q4 25 | — | 0.35× | ||
| Q3 25 | — | 0.32× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.36× | ||
| Q4 24 | — | 0.30× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $388.4M | $118.4M |
| 自由现金流经营现金流 - 资本支出 | $386.0M | $111.2M |
| 自由现金流率自由现金流/营收 | 47.9% | 12.3% |
| 资本支出强度资本支出/营收 | 0.3% | 0.8% |
| 现金转化率经营现金流/净利润 | 2.53× | 1.10× |
| 过去12个月自由现金流最近4个季度 | $743.9M | $621.1M |
8季度趋势，按日历期对齐
| Q1 26 | — | $118.4M | ||
| Q4 25 | $388.4M | $164.7M | ||
| Q3 25 | $227.5M | $191.3M | ||
| Q2 25 | $102.0M | $175.1M | ||
| Q1 25 | $64.8M | $146.9M | ||
| Q4 24 | $242.5M | $188.2M | ||
| Q3 24 | $158.0M | $146.9M | ||
| Q2 24 | $64.6M | $145.1M |
| Q1 26 | — | $111.2M | ||
| Q4 25 | $386.0M | $159.0M | ||
| Q3 25 | $214.3M | $182.8M | ||
| Q2 25 | $89.5M | $168.0M | ||
| Q1 25 | $54.1M | $140.1M | ||
| Q4 24 | $235.2M | $184.0M | ||
| Q3 24 | $149.9M | $139.4M | ||
| Q2 24 | $53.0M | $136.4M |
| Q1 26 | — | 12.3% | ||
| Q4 25 | 47.9% | 17.4% | ||
| Q3 25 | 27.0% | 17.8% | ||
| Q2 25 | 13.0% | 16.8% | ||
| Q1 25 | 9.4% | 17.0% | ||
| Q4 24 | 37.5% | 22.1% | ||
| Q3 24 | 24.1% | 15.2% | ||
| Q2 24 | 9.0% | 15.3% |
| Q1 26 | — | 0.8% | ||
| Q4 25 | 0.3% | 0.6% | ||
| Q3 25 | 1.7% | 0.8% | ||
| Q2 25 | 1.8% | 0.7% | ||
| Q1 25 | 1.9% | 0.8% | ||
| Q4 24 | 1.2% | 0.5% | ||
| Q3 24 | 1.3% | 0.8% | ||
| Q2 24 | 2.0% | 1.0% |
| Q1 26 | — | 1.10× | ||
| Q4 25 | 2.53× | 1.41× | ||
| Q3 25 | 1.09× | 1.17× | ||
| Q2 25 | 0.95× | 1.24× | ||
| Q1 25 | 8.20× | 1.40× | ||
| Q4 24 | 2.35× | 1.78× | ||
| Q3 24 | 1.22× | 1.07× | ||
| Q2 24 | 0.99× | 1.12× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NBIX
| INGREZZA Net Product Sales | $653.8M | 81% |
| CRENESSITY Net Product Sales | $135.4M | 17% |
| Other Income | $12.6M | 2% |
| Collaboration Revenue | $7.2M | 1% |
ROL
暂无分部数据
